Clinical Trials
27 trialsNCT03186118 2026-06-05
Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT07614022 2026-06-05
A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)
Wake Forest University Health Sciences
Phase 1 Not yet recruiting
NCT07586618 2026-06-03
ALT-101
Allterum Therapeutics, Inc
Phase 1 Recruiting
NCT05515406 2026-05-29
A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL
Ono Pharmaceutical Co., Ltd.
Phase 1 Terminated
NCT03219450 2026-05-28
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT07464951 2026-05-27
CART123
Children's Hospital of Philadelphia
Phase 1 Recruiting
NCT02787369 2026-05-19
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT03326921 2026-05-18
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 1 Recruiting
NCT06522373 2026-05-15
Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT06649006 2026-05-13
Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
Amgen
Phase 1 Completed
NCT07573111 2026-05-13
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Laguna Biotherapeutics, Inc.
Phase 1 Not yet recruiting
NCT03770429 2026-05-11
AZD6738 for Patients With Progressive MDS or CMML
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT07556757 2026-04-29
A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
ImmunityBio, Inc.
Phase 1 Recruiting
NCT01044069 2026-04-27
Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT03829540 2026-04-27
CD4CAR for CD4+ Leukemia and Lymphoma
Indiana University
Phase 1 Recruiting
NCT05983965 2026-04-17
Study of Tazemetostat in Lymphoid Malignancies
University of Alabama at Birmingham
Phase 1 Terminated
NCT06001788 2026-04-14
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1 Recruiting
NCT02381886 2026-04-13
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Novartis
Phase 1 Active not recruiting
NCT06021600 2026-04-09
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT07518329 2026-04-08
Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.
Arovella Therapeutics Ltd
Phase 1 Not yet recruiting
NCT07518654 2026-04-08
ThINKK-01
St. Justine's Hospital
Phase 1 Not yet recruiting
NCT04024761 2026-04-03
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT05544968 2026-04-03
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Medical College of Wisconsin
Phase 1 Recruiting
NCT06313437 2026-03-25
Revumenib in Combination With 7+3 + Midostaurin in AML
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT04629729 2026-03-19
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Phase 1 Active not recruiting
NCT06152809 2026-03-18
CIML NK Cells With Venetoclax for AML
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT05735184 2026-03-13
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
Phase 1 Recruiting